Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
"We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr. Miralles was engaged in the development and approval of several important medicines. He is an accomplished life sciences executive and his perspective in guiding life sciences companies will provide our board with valuable insights as we look ahead to key clinical development and operating milestones."
Dr. Miralles has served as Chief Executive Officer at AZURNA Therapeutics, Inc., a private pharmaceutical development company, since January 2024. From December 2020 to September 2022, Dr. Miralles was Chief Executive Officer at Laronde Inc., an early-stage biotechnology company. From August 2017 to September 2020, Dr. Miralles served as Chief Executive Officer at Vividion Therapeutics, Inc., a private biopharmaceutical company. From October 2007 to March 2016, Dr. Miralles held executive positions of increasing responsibility leading various research and clinical development programs at Johnson & Johnson. Dr. Miralles has served on the board of directors of Artiva Biotherapeutics, Inc., a publicly traded biotechnology company, since May 2024 and in January 2025, he was appointed as chair of the Clinical Strategy Committee. Dr. Miralles has also been a member of the board of directors at Rady Children's Institute for Genomic Medicine since 2008 and served as a member of the board of directors at NeuBase Therapeutics, Inc., a public biopharmaceutical company, from April 2019 to April 2021. Dr. Miralles received his M.D. degree from the University of Buenos Aires, his residency in Internal Medicine at the Mayo Clinic and fellowship in Infectious Diseases at The New York Hospital/Cornell University and was on the faculty at Duke University.
"I am impressed with Contineum's progress as it works to meet the significant unmet needs in several NI&I indications," stated Dr. Miralles. "The Company's robust pipeline enables multiple opportunities with de-risked, clinically-validated targets. I am thrilled to join a passionate board of directors with a unified vision to help guide the Company as it initiates multiple proof-of-concept clinical trials."
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit www.contineum-tx.com.
Forward-Looking Statements
Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the Company's plans for, and the anticipated benefits of, and market opportunities for its drug candidates, including PIPE-791 and PIPE-307; its business strategies and plans; and the quotations of the Company's management and board members. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control and may cause its actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval; the results of earlier preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company's drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to our competitors; risks associated with reliance on third parties to successfully conduct clinical trials and, in the case of PIPE-307, the Company's reliance, pursuant to a global license and development agreement, upon Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop PIPE-307 for any other indication other than RRMS and, after completion of the Company's PIPE-307 Phase 2 VISTA trial, Janssen Pharmaceutica NV's decision, in its sole discretion, whether or not to further develop PIPE-307 for RRMS; the Company has incurred significant operating expenses since inception and it expects that its operating expenses will continue to significantly increase for the foreseeable future; the Company's license agreement with Janssen Pharmaceutica NV may not result in the successful development of PIPE-307; the Company may be unable to obtain, maintain and enforce intellectual property protection for its technology and drug candidates; and unstable market and economic conditions and military conflict may adversely affect our business and financial condition and the broader economy and biotechnology industry. Additional risks and uncertainties that could affect the Company's business, operations and results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in its most recent filing on Form 10-K and in other filings that it makes with the SEC from time to time. These documents are available on the Company's website at www.contineum-tx.com under the Investor section and on the SEC's website at www.sec.gov. Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317917183/en/
Contacts
Steve KunszaboContineum TherapeuticsSenior Director, Investor Relations & Corporate Communications858-649-1158skunszabo@contineum-tx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
FPT Becomes SAP PartnerEdge, Sell Partner in Singapore, Malaysia, and Thailand
BUSINESS WIRE)--Global technology corporation FPT has joined the SAP PartnerEdge program as a Sell partner in selected countries in Southeast Asia. With an initial focus on Singapore, Malaysia, and Thailand, this strategic expansion further strengthens FPT's expertise in digital transformation, opening new avenues for regional enterprises to accelerate cloud adoption, streamline operations, and drive innovation with SAP's industry-leading solutions. Through the SAP PartnerEdge program, FPT is now expanding its capabilities to offer an even broader suite of SAP solutions, providing end-to-end support for businesses' digital transformation. Through the SAP PartnerEdge program, FPT is now expanding its capabilities to offer an even broader suite of SAP solutions, including SAP Cloud ERP, SAP Cloud ERP Private, SAP Business Technology Platform (SAP BTP), and more. This enables the tech firm to seamlessly integrate these solutions with its own services, providing end-to-end support for businesses' digital transformation, ranging from consultation to implementation and ongoing optimization. By combining SAP's robust platform with FPT's expertise in AI and industry-specific solutions, the collaboration also deepens FPT's engagement with SAP's global ecosystem, allowing businesses across sectors to access tailored, integrated solutions that facilitate a faster and more efficient path to digital success. As part of this expansion effort, FPT also announces the launch of the FPT Center of Excellence (CoE) for SAP Cloud, a strategic initiative designed to accelerate the adoption of SAP Cloud solutions and SAP Business Suite across Southeast Asia. The FPT CoE will serve as a hub for innovation, driving significant value for both FPT and its customers while advancing cloud-powered transformation for regional enterprises—an essential step in leveraging the full potential of AI. 'Becoming an SAP PartnerEdge, Sell partner reinforces our commitment to delivering seamless, high-impact solutions for both existing customers and regional enterprises seeking innovation,' said Tristan Ngo Minh Tri, FPT Software Vice President and Director of Enterprise Business Services Unit, FPT Corporation. 'With over 1,500 certified consultants, deep expertise in SAP technologies, and the Best-Shore Delivery Model, FPT is poised to drive transformative change and empower organizations to fully harness the potential of intelligent transformation, enabling them to drive sustainable growth and stay ahead in an increasingly digital world,' he added. 'As the first partner headquartered in Southeast Asia to join the SAP Regional Strategic Services Partner initiative, FPT has deepened its collaboration with SAP and is now an SAP PartnerEdge, Sell partner in Singapore, Malaysia, and Thailand. Congratulations to FPT for meeting the program entry requirements. We look forward to driving more impactful, AI-powered business outcomes for our customers, together,' said Deepak Kaushik, Chief Partner Officer, SAP Southeast Asia. FPT's collaboration with SAP dates back to 2003, marked by a series of successful digital transformation initiatives across key sectors such as manufacturing, BFSI, and energy. In 2023, FPT advanced the collaboration by joining the SAP® Regional Strategic Services Partner (RSSP) initiative, designed to expand the capabilities and reach of established partners within the APJ region. Building on the momentum, FPT also launched FPT BTP Park in 2025 to accelerate the growth of the SAP Business Technology Platform (SAP BTP) adoption in Japan. Over more than two decades, FPT's commitment to excellence has been recognized with multiple SAP accolades, including SAP Partner of the Year for Vietnam for 6 consecutive years, Outstanding Performance in Midmarket Partner of the Year 2025, Best RISE Partner of the Year 2025, and SAP APJ Partner Excellence Award 2025 for Regional Strategic Services Partner. SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies. About FPT FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam and operates in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. Committed to elevating Vietnam's position on the global tech map and delivering world-class AI-enabled solutions for global enterprises, the Corporation focuses on three critical transformations: Digital Transformation, Intelligence Transformation, and Green Transformation. In 2024, FPT reported a total revenue of USD 2.47 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT's global IT services, please visit
Business Insider
27 minutes ago
- Business Insider
Nvidia or AMD: Billionaire Ken Griffin Goes All-In on One Top AI Chip Stock
AI has been Wall Street's obsession for quite some time now, with investors excited about how the game-changing tech is set to transform our world in many ways, from reshaping business models and driving productivity gains to creating entirely new markets and industries. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The technology is widely seen as one of the most transformative forces of our era – yet, according to investing legend Ken Griffin, the most meaningful chapters are still unwritten. 'Generative AI has just gripped the world both in mind-share impact and to some degree hype… Generative AI is just another step in the journey of the use of machine learning technologies by modern society… I think the really interesting generative AI stories are going to be when people think about how to use these tools in radically different ways than we currently use software, and those will be many of the game-changing businesses of the next 10 to 20 years. So it's going to be incredibly exciting,' Griffin opined. Griffin is backing up his words with action. With a net worth north of $47 billion, the founder and CEO of Citadel – one of the world's most profitable hedge funds, managing $68 billion in capital – has been leaning heavily into the AI opportunity. Citadel's portfolio boasts some of the most prominent AI stocks out there, including Nvidia (NASDAQ:NVDA) and Advanced Micro Devices (NASDAQ:AMD). However, during Q2, Griffin loaded up on one of these yet trimmed his holdings of the other. So, we've decided to take a closer look at the pair to see why Griffin has more conviction in one of these names right now, and with a little help from the TipRanks database, we can also find out if the Street's analyst community is thinking along the same lines. Nvidia What better place to start than at the altar of the mightiest AI stock of them all? The current bull market might be an AI-driven one, but you might as well call it the Nvidia bull market. That's because AI's rise has coincided with Nvidia's march to the top of the market cap charts, with the firm transforming from merely a semiconductor giant to becoming the world's most valuable company. That transformation has been powered by one critical fact: Nvidia makes the best AI chips on the market – the ones driving the data centers that fuel this technological revolution. Under Jensen Huang's leadership, the company now commands more than an 80% share of this space, leaving rivals scrambling to keep pace. It's a remarkable shift for a firm that, not long ago, was better known for supplying GPUs to gamers. Wall Street first took notice when its data center segment exploded into Nvidia's primary growth engine, and the company has since built a track record of delivering blockbuster quarterly results. Even trade restrictions and China-related headwinds haven't derailed its momentum, as demonstrated in its last reported fiscal Q1 quarter. (April quarter). Revenue surged to $44.06 billion, up 69.2% year-over-year and ahead of consensus by $810 million. Data Center revenue accounted for $39.1 billion of that total, a 73% annual jump. Earnings strength followed suit, with adjusted EPS of $0.81 beating forecasts by $0.06. With all of that on offer, Ken Griffin has signaled that he wants in. During Q2, he upped his NVDA stake by 414%, purchasing 6,513,348 shares. These are currently worth a whopping ~$1.175 billion. According to Piper Sandler's Harsh Kumar, an analyst ranked in 13th spot amongst the thousands of Wall Street stock experts, that investment is going to pay off nicely. Looking ahead to the upcoming July quarter readout (slated for August 27), Kumar thinks another strong display is coming. 'We are expecting another positive quarter from NVDA and see upside to numbers for both the July and October quarters,' the 5-star analyst said. 'While we are modeling largely in-line for the July quarter and slightly below Street for October, we are calling for upside given the recent positive commentary from U.S. hyperscalers as well as the inclusion of revenues from China. We note that our estimates and Street estimates do not reflect the inclusion of China business as we are anticipating revenues to start coming in towards the end of this month. China demand in our view could amount to ~$6B in sales for the October quarter and further ramp from there at a ~12-15% growth rate moving forward in a normal quarter. Finally, we are encouraged by hyperscaler commentary around capex plans for 2H and 2026 which should continue to pressure NVDA to meet this demand.' Quantifying his bullish stance, Kumar rates NVDA shares as Overweight (i.e., Buy) while his $225 price target factors in a one-year gain of 25%. (To watch Kumar's track record, click here) The majority of Kumar's colleagues support that stance; NVDA claims a Strong Buy consensus rating, based on a mix of 35 Buys, 2 Holds and 1 Sell. (See NVDA stock forecast) AMD There is really no better stock to delve into next than AMD, a statement that is something of both a compliment and a curse. A compliment because AMD is seen as possibly the only other semi name out there that can challenge Nvidia's dominance in the AI chip world. Moreover, AMD has already proven itself adept at eroding another rival's rule over a particular segment. Intel used to be the undisputed leader of the CPU space, but by making the most of Intel's mistakes and offering better products, AMD has been steadily closing the gap on the fallen chip giant's leading position in that sector. But the very fact that AMD is measured against Nvidia is what makes the comparison something of a curse. Despite its achievements, AMD has often been saddled with 'little bro' status. The perception persists that AMD is simply second-best in the AI chip game, lacking the complete ecosystem that Nvidia offers, and forced to play catch-up in a market it entered much later. And unlike struggling Intel, Nvidia isn't a weakened rival – it's still firing on all cylinders, making the bar for AMD that much higher. Even so, it's important not to overlook AMD's own impressive trajectory. While Nvidia may have stolen the spotlight, AMD has continued to deliver solid results and carve out its share of wins. The company's recent Q2 readout underscored that point. Revenue climbed by 31.7% year-over-year, reaching $7.69 billion and outpacing analyst expectations by $260 million. At the bottom line, adjusted EPS of $0.48 landed in line with consensus estimates. Looking ahead, AMD projects Q3 revenue of $8.7 billion, plus or minus $300 million, well above the Street's forecast of $8.32 billion. In fact, this outlook didn't even factor in revenue from shipments to China, which had been banned at the time but are now allowed again. The market has taken notice. AMD shares have surged 127% since April's tariff-driven lows, a rally that may explain why Griffin has been trimming his stake. In Q2, the billionaire sold 2,433,332 AMD shares, cutting 67% of his holdings. That kind of caution is mirrored in recent comments made by Morgan Stanley analyst Joseph Moore, who wrote: 'AMD revenue continues to be quite strong, but it's not clear that will be enough to keep the bulls in charge of the narrative. AMD guided well above consensus for Q3, but there are a few factors of note here that make the topline strength less appealing: (1) Console gaming upside drove the beat in Q2, arguably the lowest quality portion of AMD's business, (2) datacenter GPU will be up y/y in Q3, implying 1.6bn+ by our estimates; combined with company commentary for strong server and growth in embedded and client, we don't think it's likely to be more than 100- 200mn more than that…(3) Opex coming in above estimates limits impact on EPS.' To this end, the 5-star analyst rates AMD an Equal-Weight (i.e., Neutral) while his $168 price target implies shares will slide by 5% over the coming months. (To watch Moore's track record, click here) To find good ideas for AI stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
an hour ago
- Yahoo
Clean Jeju Green Tea Cooperative ‘Sumang' to Launch New Hojicha Product This August
JEJU, South Korea, August 18, 2025--(BUSINESS WIRE)--Clean Jeju Green Tea Agricultural Cooperative 'Sumang' has announced that it plans to launch a new product—Hojicha—in August. Hojicha is a roasted green tea made by pan-firing tea leaves at high temperatures, known for its rich, nutty aroma and low caffeine content. Sumang is a vertically integrated producer that grows, processes, and sells organic green tea in Jeju Island. Benefiting from ideal tea-growing conditions—including proximity to the sea, warm temperatures, and frequent mist—the cooperative has been able to cultivate high-quality tea with a consistent moisture supply during the growth period. Recently, global interest in health and wellness has fueled rising demand for matcha, particularly in the United States. Exports have been steadily rising, and inquiries from international buyers are also growing. While many matcha products are flooding the market, consumers often struggle to find high-quality, properly graded matcha. The cooperative's "Sumang Tea Garden" brand offers matcha in three distinct grades: Ceremonial, Premium, and Superior, giving consumers a variety of options tailored to their taste and intended use. CEO Kyungmin Kang said, "While we currently focus on B2B transactions, our ultimate goal is to expand into direct-to-consumer channels with a comprehensive distribution network," adding, "We are committed to offering high-quality products at affordable prices." About Sumang Since 2007, Sumang has produced Jeju green tea of the highest quality, provided by the natural environment of Jeju Island, South Korea. Abiding by the strict rules of the Clean Jeju Green Tea Agricultural Cooperative, Sumang offers products that promote both health and environmental sustainability. View source version on Contacts SumangKyungmin Kang+82-64-739-8033tolkm@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
